APA (7th ed.) Citation

Feldt-Rasmussen, U., Watt, T., Burlina, A., Cazzorla, C., Schönfeld, D., Banikazemi, M., . . . O'Brien, F. (2012). P20—Agalsidase Beta Treatment is Associated With Improvement in Quality of Life in Patients With Fabry Disease: Findings From the Fabry Registry. Clinical Therapeutics, 34, e26. https://doi.org/10.1016/j.clinthera.2012.03.049

Chicago Style (17th ed.) Citation

Feldt-Rasmussen, U., et al. "P20—Agalsidase Beta Treatment Is Associated With Improvement in Quality of Life in Patients With Fabry Disease: Findings From the Fabry Registry." Clinical Therapeutics 34 (2012): e26. https://doi.org/10.1016/j.clinthera.2012.03.049.

MLA (9th ed.) Citation

Feldt-Rasmussen, U., et al. "P20—Agalsidase Beta Treatment Is Associated With Improvement in Quality of Life in Patients With Fabry Disease: Findings From the Fabry Registry." Clinical Therapeutics, vol. 34, 2012, p. e26, https://doi.org/10.1016/j.clinthera.2012.03.049.